The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis.
H. Prenen
No relevant relationships to disclose
R. Geva
No relevant relationships to disclose
H. Piessevaux
No relevant relationships to disclose
S. Tejpar
Honoraria - Merck Serono
Research Funding - Merck Serono
C. Verslype
No relevant relationships to disclose
J. Vannoote
No relevant relationships to disclose
L. Mortier
No relevant relationships to disclose
E. Van Cutsem
Consultant or Advisory Role - Roche
Research Funding - Roche